drugset / Trial / NCT05747664
To Compare the Safety and PK/PD Characteristics of Subjects With Between Hepatic Impairment and Normal Hepatic Function
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This study aims to evaluate the pharmacokinetics, pharmacodynamics, safety, and tolerability of DWP16001 in subjects with hepatic impairment compared with subjects with normal hepatic function.
Timeline
- Start
- 2023-04-13
- Primary completion
- 2024-04-30
- Completion
- 2024-04-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Enavogliflozin | Small molecule | 0.3 mg | Oral |